BTIG analyst Justin Zelin raised the firm’s price target on Syndax (SNDX) to $56 from $43 and keeps a Buy rating on the shares. The company delivered strong Q2 results, with Revuforj and Niktimvo both posting breakout commercial performance that exceeded both internal and external expectations for the quarter and surpassed benchmarks set by precedent AML launches, the analyst tells investors in a research note. Syndax is on a clear path to profitability with both launches cash flow contributors, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
